News Kelun's MSD-partnered TROP2 drug gets first okay in China Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
News Adcendo raises $135m for cancer ADCs, and other financings Adcendo raises $135m for cancer ADCs, plus financings for Enveda, Cradle Bio, ATB Therapeutics, and 35Pharma
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.